1146629-75-5

Basic information

• Product Name: (4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
• Synonyms: (4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
• CAS NO: 1146629-75-5
• Molecular Formula: C₁₂H₁₄ClN₃O₂
• Molecular Weight: 267.71146
• Mol File: 1146629-75-5.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 390.0±32.0 °C(Predicted)
• Appearance: /
• Density: 1.30±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 2.81±0.30(Predicted)
• CAS DataBase Reference: (4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate(1146629-75-5)
• EPA Substance Registry System: (4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate(1146629-75-5)

Safety Data

• Hazardous Substances Data: 1146629-75-5(Hazardous Substances Data)

Usage

Uses

(4-Chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate?can be used as a heterocyclic derivative for pharmaceutical synthesis.

Upstream product

• 18997-19-8 Chloromethyl pivalate 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 55052-28-3 4-chloro-7-azaindole 

Downstream Products

• 1146629-77-7 [4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl 2,2-dimethylpropanoate 
• 1187594-09-7 Baricitinib 
• 1187595-90-9 (4-{1-[3-(cyanomethyl)-1-(ethylsulphonyl)azetidin-3-yl]-1H-pyrazol-4-yl}-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl 2,2-dimethylpropanoate 
• 1298084-48-6 (4-(6-(3-nitrophenyl)-1H-indole-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-7-yl)methyl pivalate 
• 1298084-30-6 N-(3-(1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-indol-6-yl)phenyl)-4-chloro-3-(trifluoromethyl)benzamide 
• 1298084-29-3 1-(3-(1-(7H-pyrrolo[2,3-d]pyrimidine-4-yl)-1H-indole-6-yl)phenyl)-3-(2-methoxyphenyl)urea 
• 1298084-47-5 (4-(6-(3-aminophenyl)-1H-indole-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-7-yl)methyl pivalate 

Relevant articles and documents

Synthesis and Characterization of Compounds Potentially Related to the Janus Kinase Inhibitor Baricitinib

Nine compounds potentially related to the Janus kinase inhibitor Baricitinib have been identified, synthesized by conventional methods, and characterized by IR, 1H and 13C NMR, and mass spectral data.

Pyrrolo[2, 3-d] pyrimidine derivatives containing piperidine as well as preparation and application thereof

The invention relates to a piperidine-containing pyrrolo[2, 3-d] pyrimidine derivative as shown in a general formula I or a general formula II as well as a use method and a preparation method thereof.The invention also relates to a strong JAK kinase inhibition effect of the compound shown in the general formula I or II, the invention also relates to an application of the compound in preparation of medicines for treating and/or preventing diseases caused by abnormal expression of JAK, and particularly relates to application of the compound in preparation of medicines for treating inflammatory/autoimmune diseases, fibrosis and cancers.

JAK KINASE INHIBITOR AND PREPARATION METHOD AND USE THEREOF

Provided in the present invention are a new type JAK kinase selective inhibitor and a preparation method and the use thereof. In particular, disclosed are a compound having the structure as shown in chemical formula (I) as a JAK kinase inhibitor or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof.